

Philipp Gauckler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5250243/publications.pdf>

Version: 2024-02-01

19
papers

406
citations

1162367

8
h-index

839053

18
g-index

19
all docs

19
docs citations

19
times ranked

667
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19: implications for immunosuppression in kidney disease and transplantation. <i>Nature Reviews Nephrology</i> , 2020, 16, 365-367.	4.1	87
2	Immunopathogenesis of ANCA-Associated Vasculitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7319.	1.8	62
3	Refractory lupus nephritis: When, why and how to treat. <i>Autoimmunity Reviews</i> , 2019, 18, 510-518.	2.5	52
4	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.4	39
5	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	2.5	37
6	Comorbidities in ANCA-associated vasculitis. <i>Rheumatology</i> , 2020, 59, iii79-iii83.	0.9	34
7	Eosinophilia and Kidney Disease: More than Just an Incidental Finding?. <i>Journal of Clinical Medicine</i> , 2018, 7, 529.	1.0	25
8	ANCA Status or Clinical Phenotype – What Counts More?. <i>Current Rheumatology Reports</i> , 2021, 23, 37.	2.1	14
9	Immunoabsorption in nephrotic syndrome: Where are we now and where are we going from here?. <i>Atherosclerosis Supplements</i> , 2019, 40, 55-60.	1.2	9
10	Rituximab in minimal change disease and focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 983-985.	0.4	8
11	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907.	0.4	8
12	Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic. <i>European Journal of Rheumatology</i> , 2020, 7, S121-S128.	1.3	8
13	What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 669-671.	0.5	7
14	The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 760708.	2.2	7
15	Edema-like symptoms are common in ultra-distance cyclists and driven by overdrinking, use of analgesics and female sex – a study of 919 athletes. <i>Journal of the International Society of Sports Nutrition</i> , 2021, 18, 73.	1.7	3
16	Lessons learned from immunoabsorption for hyperviscosity in IgM multiple myeloma – A case report. <i>Journal of Clinical Apheresis</i> , 2020, 35, 227-230.	0.7	2
17	The Role of Rituximab in Focal Segmental Glomerulosclerosis – Update From Italy. <i>Kidney International Reports</i> , 2022, 7, 1731-1733.	0.4	2
18	Response to: – Correspondence on – What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern – by Hakrrouch and Tampe. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrhumdis-2020-219696.	0.5	1

#	ARTICLE	IF	CITATIONS
19	Response to: "Correspondence on "What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern" by Hocevar <i>et al</i> . Annals of the Rheumatic Diseases, 2023, 82, e147-e147.	0.5	1